Edwards Lifesciences Corporation Stock News

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.

IRVINE, Calif., April 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20

Edwards Lifesciences has shown consistent earnings and revenue growth in the last few years and it has strong profitability measurements. The company is scheduled to report first quarter earnings resu

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B) disclosed on Tuesday its fourth-quarter 2020 portfolio, revealing new holdings in Verizon Inc. (NYSE:VZ), Chevron

AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve wit

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q4 2020 Results - Earnings Call Transcript

While technology stocks remain hot in 2021, there are other sectors that should be on your radar this earnings season.

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -5.66% and 0.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Edwards Lifesciences (NYSE:EW) decreased 4.5% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 65.75% over the past year to $0.50

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, Janu

Edwards Lifesciences is a quality name that sits at the tip of the spear in cardiovascular value procedure offerings. The company has remained resilient in the face of the pandemic, and is well positi

IRVINE, Calif., Dec. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and